BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MTI Biotech Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MTI Biotech Inc.'s drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06432166-751@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:2-hydroxybenzylamine acetate: Phase 1/2 readout est. (NCT06432166)
DESCRIPTION:2-hydroxybenzylamine acetate\, phase 1/2\, Alzheimer's Disease.
 \nStudy: 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
 \nEstimated primary completion: 30 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/2-hydroxybenzylamine-acetate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06432166
URL:https://assetmemo.bio/drug/2-hydroxybenzylamine-acetate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
